

SURMODICS INC  
Form 8-K  
April 09, 2019  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

April 9, 2019  
Date of report (Date of earliest event reported)

Surmodics, Inc.  
(Exact Name of Registrant as Specified in its Charter)

Minnesota                      0-23837                      41-1356149  
(State of Incorporation) (Commission File Number) (I.R.S. Employer  
Identification No.)

9924 West 74<sup>th</sup> Street  
Eden Prairie, Minnesota                      55344  
(Address of Principal Executive Offices) (Zip Code)

(952) 500-7000  
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8 K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a 12 under the Exchange Act (17 CFR 240.14a 12)

Pre commencement communications pursuant to Rule 14d 2(b) under the Exchange Act (17 CFR 240.14d 2(b))

Pre commencement communications pursuant to Rule 13e 4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section

13(a) of the Exchange Act.

---

Item 7.01 Regulation FD Disclosure.

Surmodics, Inc. (the “Company”) will make a presentation at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019. A copy of the presentation materials to be used in conjunction with the conference is attached to this report as Exhibit 99.1. A complete copy of the presentation materials will be made available in the investor section of the Company’s website at [www.surmodics.com](http://www.surmodics.com).

The information in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under Section 18, nor shall such information be deemed incorporated by reference into any filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit<br>Number | Description                      |
|-------------------|----------------------------------|
| 99.1              | Investor Presentation Materials. |

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SURMODICS, INC.

Date: April 9, 2019 /s/ Bryan K. Phillips  
Bryan K. Phillips  
Sr. Vice President, Legal and Human Resources,  
General Counsel and Secretary

---

EXHIBIT INDEX

| Exhibit<br>Number | Description |
|-------------------|-------------|
|-------------------|-------------|

|             |   |
|-------------|---|
| <u>99.1</u> | <u>Investor Presentation Materials.</u> |
|-------------|---|